Executive Summary
First oral OX2R agonist to demonstrate efficacy across narcolepsy type 1, type 2, and idiopathic hypersomnia
ORX750
OX2R · OX2R agonist
Mechanism of Action
TypeSelective OX2R agonist (small molecule)
DescriptionORX750 is a potent, selective, orally bioavailable agonist of the orexin receptor 2 (OX2R). By directly activating OX2R, it mimics the wake-promoting effects of endogenous orexin, restoring the signal that is lost or impaired in narcolepsy and hypersomnia.
Indications: Narcolepsy Type 1 (NT1)Narcolepsy Type 2 (NT2)Idiopathic Hypersomnia (IH)
Target Biology
Orexin neurons in the hypothalamus produce orexin-A and orexin-B neuropeptides that bind to OX1R and OX2R receptors. OX2R activation promotes wakefulness, stabilizes sleep-wake transitions, and supports arousal. In narcolepsy type 1, orexin neurons are destroyed by autoimmunity, causing severe daytime sleepiness and cataplexy.
Human Genetic Evidence: Loss of orexin neurons causes narcolepsy type 1 with cataplexy
Clinical Data
No clinical trial data available.
Market Opportunity
Unmet Need: NT2 and IH are severely underserved. An oral, well-tolerated OX2R agonist could transform treatment paradigm.
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Registrational program initiation | Q1 2026 | critical | Study design, endpoint selection, dose chosen for registrational study | — |
| Additional CRYSTAL-1 dose cohort data | 2026 | high | Higher dose efficacy and safety to further characterize dose-response | — |
| Registrational program initiation (CRYSTAL registrational study) | Q1 2026 | critical | — | — |
| Additional CRYSTAL-1 Phase 2a dose cohort data | 2026 | high | — | — |